ライフサイエンスコーパス: setting where

1 n analyses stratified by country, we found 3 settings where drought was protective for at least 1 mea

2 cases of infection through breastfeeding, a setting where it is not always possible to initiate earl

3 In a setting where daily complementary food supplementation i

4 We tested for CH in a setting where hematopoietic stem cells (HSCs) of the sam

5 In a setting where HIV care is well organized and antiretrovi

6 approach will have the greatest effect in a setting where implementation of optical coherence tomogr

7 s for inferring functional connectivity in a setting where input to the neuron is controlled.

8 EP to new methods examine effectiveness in a setting where only one or the other is provided; however

9 We explore concordance in a setting where racial disparities are particularly severe

10 al variables would not predict survival in a setting where surgical techniques were standardized and

11 hese are important findings, especially in a setting where the concrete BSF has seen high rates of co

12 d (LOCF), and multiple imputation (MI), in a setting where time-dependent covariates also act as medi

13 illness, the intensive care unit (ICU) is a setting where death is common.

14 ulated during oncogene-induced senescence, a setting where it acts in response to p53 as a direct tra

15 in metastatic RCC as second-line therapy, a setting where no effective systemic therapy is presently

16 significant economic impact in the adjuvant setting where the drug is arbitrarily given for 1 year.

17 erefore, we recommend rolling out SDR in all settings where contact tracing and screening have been e

18 roponin testing, including in the ambulatory setting, where assessment for low-level chronic myocardi

19 odulate myeloid cell functions in anatomical settings where PILRalpha ligands are expressed.

20 nt technique suitable to diamond powders and settings where the field is heterogeneous.

21 were included if they were performed in any setting where suicide completions, suicide attempts, or

22 vances have helped delineate the appropriate settings where inhibiting or promoting autophagy may con

23 al cost or duration considerably, as well as settings where potential savings are negligible.

24 attractive treatment strategy in autoimmune settings where monotherapy is not fully effective.

25 This is quite disparate to the H-2(b) setting, where only two epitopes have been identified.

26 al regulatory mechanisms in other biological settings where analogous genomic data are available.

27 l new tool for matrix analysis in biological settings, where the relationship of observed quantities

28 ule-in value than ADA in this high-TB-burden setting where HIV is endemic.

29 This may be of importance in high-burden settings where > or =1 genetic group of M. tuberculosis

30 ticularly those practicing in the acute care setting where rapid pathogen detection and identificatio

31 ticularly those practicing in the acute-care setting, where rapid pathogen identification may assist

32 In the South African HIV care setting-where TB mortality rates are higher and Ultra's

33 of people living with dementia in acute care settings where the institutional drivers of routines, ef

34 ia testing in public and private health care settings where there are challenges to blood-based malar

35 ent by uninfected individuals in health-care settings where they may be at increased risk of infectio

36 based detection assays towards point-of-care settings where they are needed most.

37 with isolated fast breathing in primary care settings where hospital referral is often unfeasible.

38 ese results may not be generalizable to care settings where on-site physician HIV experts are not acc

39 ever, its performance in routine health care settings, where adherence to drug treatment is unsupervi

40 y in drug treatment centers and primary care settings, where omitted HCV RNA analyses had absolute re

41 ting that the interaction occurs in cellular settings where ABCA1 activity is critical for HDL genesi

42 y cells, like monocyte/macrophages, cellular settings where these epigenetic reader proteins couple p

43 ncertainty quantification in the challenging setting where the reaction graph is unknown.

44 lopment interventions offered through clinic settings, where access to high-risk adolescents is plent

45 ests for Legionnaires' disease in a clinical setting where Legionella pneumophila PCR had been introd

46 es or provide decision support in a clinical setting where the choice and timing of therapies are cri

47 the mean number of visits, and the clinical setting where care was provided.

48 ession results, particularly in the clinical setting where fold-change differences are typically smal

49 ariability is concerning within the clinical setting where oftentimes BP measurement site is not stan

50 This is critically important in the clinical setting where targeted resequencing is frequently being

51 In a clinical setting, where a change in cTnT was not mandatory for th

52 with the test's accuracy, even in a clinical setting, where operator training is mandated.

53 l differences and be applied in the clinical setting, where patients must be assessed as individuals.

54 ues is of great significance in the clinical setting, where therapeutic strategies for modulating the

55 There may be clinical settings where and populations in whom accessing or mana

56 stic tool that can be developed for clinical settings where ease of handling and minimal sample prepa

57 patients for AG-sparing regimens in clinical settings where access is limited.

58 emains challenging, particularly in clinical settings where accuracy and turnaround times are critica

59 t, and this approach may be used in clinical settings where autologous HSC transplant is being perfor

60 ble effects of certain additives in clinical settings where enhanced immune responsiveness can transl

61 In clinical settings where FMT is not available or applicable, the p

62 that has been minimally studied in clinical settings where it might be problematic, such as in peopl

63 ings bear potential implications in clinical settings where proteasome peptidase activities are thera

64 its utility has been questioned in clinical settings where the prevalence of OM is low.

65 w approach to prevent thrombosis in clinical settings where the risk of clotting is high.

66 c system as well as in some limited clinical settings where real-time visible fluorescence could faci

67 ensors, has proven helpful in other clinical settings where low mean arterial pressure and need for a

68 ially away from controlled, sterile clinical settings where wounds urgently require protection from e

69 the gut microbiome in research and clinical settings, where it is important to adhere to strict timi

70 phenotypes, limiting their role in clinical settings, where hundreds of diagnoses must be considered

71 ry assays, impractical in real-time clinical settings, where the information is most urgently needed.

72 rategies for detecting dementia in community settings where biomarkers may not be readily available,

73 reak investigations in hospital or community settings where robust clones are endemic.

74 observation that has parallels in corporate settings where middle managers must interact most to ens

75 rent level of TFA intake to a counterfactual setting where consumption was lowered to a theoretical m

76 ly challenging for use in developing country settings, where vitamin A deficiency remains a major pub

77 One critical setting where these limitations are evident is the detec

78 logic management of SS, both in the curative setting, where the standard approach is wide surgical ex

79 findings have relevance for other diagnostic settings where bacterial pathogens are vulnerable to lyt

80 l studies are challenged in high-dimensional settings where interactions among variables are also imp

81 toxicity profiles in several common disease settings where conventional treatments have previously p

82 peptide-based therapeutics in human disease settings where unmet needs still exist.

83 ion "platform" trials and infectious disease settings where temporal trends are ubiquitous.

84 We posit, however, that in dynamic settings where people can observe and condition their ac

85 monitor malaria transmission in elimination settings where existing metrics such as parasite prevale

86 s known about the role of climate in endemic settings where clinical immunity develops early in life.

87 y acquired immunity are warranted in endemic settings where transmission has been reduced but persist

88 on have not been examined in non-equilibrium settings where unexpected consequences of interaction mo

89 Using an experimental setting where infected fibroblasts were cocultured with

90 In contrast to the experimental setting, where one of the two branches is often occluded

91 can limit their application in experimental settings where cell numbers are restricted, such as in v

92 ression experiments or in noisy experimental settings where a small sub-population of cells contribut

93 soils or plants and the atmosphere in field settings where exogenous tracer applications are challen

94 This suggests that in field settings where mutual shading between plants may occur,

95 ngs with extensive use of lamivudine and for settings where generic lamivudine will be available.

96 tation of a bivariate linear mixed model for settings where hundreds of traits have been measured on

97 second design uses a hierarchical model for settings where, a priori, the experimental treatment eff

98 risks framework, which refers to the general setting where scientific interest lies with some nonterm

99 and tend to accumulate in population-genetic settings where random genetic drift is a relatively stro

100 % in the city studied, 67% in the healthcare setting where they had completed a course placement.

101 ield a smaller tidal volume than typical HFO settings where frequency is limited to 6 Hz or less and

102 es but are impractical for use in a hospital setting, where Clostridium difficile spores present a ch

103 articularly relevant concern in the hospital setting, where antibiotic use and antibiotic-resistant p

104 ) therapy while highly effective in the HSCT setting where immunosuppression can be withdrawn have be

105 In hyperendemic settings where mixed infections are common, the Xpert re

106 ad contributors, and operating room identify settings where fire risk is enhanced by proximity of tri

107 We illustrate settings where incorporating genetic information could r

108 In settings where inclusion criteria are assessed after imp

109 In settings where information about pelvic-floor exercise i

110 In settings where MRSA is prevalent, clindamycin and TMP-SM

111 In settings where quarantine centres were not feasible, a c

112 In settings where so-called standard therapy is not feasibl

113 to individual probabilities being 0 or 1 in settings where the evidence is clearly not sufficient fo

114 ctious diseases has largely been achieved in settings where natural immunity to the pathogen results

115 most appropriate technologies are adopted in settings where they will have a sustainable impact.

116 est that enhancement is most advantageous in settings where multiple serotypes circulate and where a

117 ions requiring fast turnaround times, and in settings where a centralized laboratory approach faces l

118 irable, such as infection and cancer, and in settings where tolerance-driving DCs are preferred, such

119 antibodies, nanobodies have been applied in settings where the use of standard antibodies or their d

120 HIVDR mutations affecting first-line ART in settings where WHO ART guidelines are applied.

121 dye technique can be used for SLN biopsy in settings where nuclear medicine facilities are not avail

122 tudy may have important implications both in settings where the immunogenic function of DCs is desira

123 we describe a method for genotype calling in settings where sequence data are available for unrelated

124 us, but its interpretation is challenging in settings where inflammation is common because RBP concen

125 listeners report difficulty communicating in settings where there are competing sound sources, but th

126 nature of selection and its consequences in settings where focal traits vary over the lifetime throu

127 In contrast, in settings where CTLA-4(+) cells were present as "regulato

128 about how to scale up care for depression in settings where non-physician lay workers constitute the

129 haemodialysis for many patients with ESKD in settings where infrastructure permits.

130 on favorable to immunotherapy, especially in settings where donor lymphocytes are unavailable such as

131 in future and larger studies, especially in settings where mothers are more stressed, such as those

132 failure of model convergence, especially in settings where the prevalence of M. tuberculosis infecti

133 es of these types of immunity, especially in settings where there is emerging evidence of antagonism

134 icate that individuals seek abortion even in settings where it is restricted.

135 ting is recommended for all adults except in settings where there is evidence that the prevalence of

136 r in response to viral antigen was higher in settings where more severe disease occurred.

137 However, in settings where both CD4 cell counts and viral load testi

138 y for the control of scabies and impetigo in settings where the diseases are endemic.

139 r tolerance may be particularly important in settings where RTEs comprise a large fraction of the per

140 they became profoundly anti-inflammatory in settings where they would normally be classically activa

141 e conventional laboratory infrastructure, in settings where diagnosis is required at the point of sam

142 icting paired macromolecular interactions in settings where high-throughput affinity data are availab

143 ure-based surveillance or even replace it in settings where population-based clinical surveillance is

144 hould examine elective induction of labor in settings where most obstetric care is provided.

145 fected persons require revision, at least in settings where prophylaxis with this agent is common.

146 e of antimalarial drugs to infants living in settings where malaria is endemic, at the time of routin

147 nostimulatory monoclonal antibodies (mAb) in settings where the receptors targeted by the mAbs are ex

148 dy found that the disparity was magnified in settings where resources were greatest.

149 he natural mouse host infected with MCMV, in settings where virus-specific CD8 T cells are adoptively

150 without the need for BCR transgenic mice, in settings where tolerance pathways are compromised or hav

151 standard regimens and clinical monitoring in settings where laboratory infrastructure was not availab

152 uld have the greatest impact on mortality in settings where resources for HIV testing and linkage are

153 s of Mycobacterium tuberculosis may occur in settings where the infection pressure is high.

154 y-two percent of all pregnancies occurred in settings where the quintuple dhfr/dhps haplotype had bec

155 ipeptide, and that the role of NIK occurs in settings where both the Nod2 and TLR4 pathways are activ

156 endations while awaiting trial results or in settings where trials may be infeasible.

157 These data support use of oxytocin in settings where it is available.

158 at donor autonomy should not be paramount in settings where the recipient benefit is uncertain.

159 icians is therefore evident, particularly in settings where childhood tuberculosis is common, and bac

160 children with suspected PTB, particularly in settings where IS and culture are not feasible.

161 ial mortality and morbidity, particularly in settings where people lack improved sanitation and safe

162 understanding of RSV trends, particularly in settings where testing and reporting are most active.

163 ic technologies and that can be performed in settings where laboratory infrastructure is minimal.

164 associated with exposure to air pollution in settings where household biomass stoves are commonly use

165 These data inform clinical practice in settings where TB and HIV are endemic.

166 ical inoculation rates but lack precision in settings where seroprevalence is still high.

167 ould be under negative selection pressure in settings where choline intake is low: choline dehydrogen

168 o provide an improved level of protection in settings where P[6] rotavirus disease is endemic, irresp

169 g are valid measures of operative quality in settings where follow-up is poor.

170 to establish whether this effect remains in settings where infection-prevention bundles of care are

171 lume method have the best reproducibility in settings where assessment is not performed by the same p

172 Research in settings where hypothermia is common is needed to determ

173 w therapeutic avenues to boost resolution in settings where defective resolution promotes disease pro

174 ion of models for predicting disease risk in settings where A. albopictus is present.

175 vides further evidence for the use of RMS in settings where CS are unavailable or unaffordable, or re

176 ggest that the deployment of DGT samplers in settings where nanoparticles are relevant (e.g., sedimen

177 fective far sooner, and even cost-saving, in settings where long-term health-care costs of late-diagn

178 is best implemented as an initial service in settings where services are scarce, for example in rural

179 t elevation myocardial infarction (STEMI) in settings where health-care resources are scarce.

180 needed to make MSAT an effective strategy in settings where malaria elimination programs are in the p

181 h cohort, research and evaluation studies in settings where persons who inject drugs receive services

182 he safety of routine iron supplementation in settings where infectious diseases, particularly malaria

183 t women who are virologically suppressed, in settings where therapeutic drug monitoring and/or close

184 ental health improvements to be sustained in settings where they are most critical by improving trust

185 that may replace conventional GM testing in settings where GM results are not rapidly available.

186 This work provides evidence that in settings where there is a dominant source of biomass com

187 transport principles for lineage tracing in settings where existing experimental strategies cannot b

188 d times would allow more effective triage in settings where patient management and infection control

189 vention and call for effectiveness trials in settings where it could be sustainably delivered.

190 radiolabeled probes and allowing its use in settings where malaria is endemic.

191 LPAs have a continued role for use in settings where rapid identification of INH resistance an

192 CD), in the Mediterranean area, when used in settings where it was designed to be administered, espec

193 uccess rate, TAP blocks remain under used in settings where patients could most benefit from their us

194 d nested case-control designs can be used in settings where the research aim is to evaluate the predi

195 er time, and could be particularly useful in settings where influenza activity is delayed or prolonge

196 Our results are potentially useful in settings where understanding social and spatial mixing o

197 It is particularly useful in settings where uRT-qPCR is difficult to implement.

198 argeted approaches may have more validity in settings where human settlement is more nuclear.

199 t similar adducts would be formed in vivo in settings where cyclooxygenase-2 expression is increased.

200 hest preterm birth rates occur in low-income settings where the causes of prematurity might differ an

201 blic health concern especially in low-income settings where these sources are used untreated.

202 d impact studies, particularly in low-income settings, where pneumococcal disease burden remains high

203 regation is a major problem in an industrial setting where antibody therapeutics often require high l

204 in models of outdoor, indoor, and industrial settings where particles are formed, and where accurate

205 l numbers is a serious concern in industrial settings where qPCR estimates form the basis for quality

206 anisms that are relevant to the inflammatory settings where these proinflammatory cytokines play a cr

207 limited attention, especially in innovative settings where they are working together.

208 are likely to be faced in all international settings where there is increased reliance on a support

209 a versatile role - in several international settings where candidate biomedical HIV prevention inter

210 the point of injection to the intracellular setting where functional gene silencing occurs.

211 A key setting where this online hypothesis testing occurs is i

212 w period in blood donors in resource limited settings where nucleic acid testing is not practical or

213 mation systems and two from resource-limited settings where clinicians maintain locally developed dat

214 of HIV-1 drug resistance in resource-limited settings where combination antiretroviral treatment has

215 periodontitis screening in resource-limited settings where gold standard clinical examination may no

216 patient care, especially in resource-limited settings where laboratory infrastructure is poor and the

217 In resource-limited settings where no safe alternative to breastfeeding exis

218 INTERPRETATION: In resource-limited settings where no suitable alternative to breastfeeding

219 and third-line regimens in resource-limited settings where subtype C predominates.

220 s have impeded their use in resource-limited settings where such diseases are endemic.

221 t is an emerging problem in resource-limited settings where, in efforts to stem mother-to-child-trans

222 lly positive, especially in resource-limited settings, where the majority of vulnerable populations r

223 thology applications and in resource-limited settings, where whole-slide scanning microscopy systems

224 ls, primary care clinics and EDs are logical settings where screening that leads to intervention can

225 he context of real-world clinical management settings, where varying durations of and gaps in treatme

226 through Phanerozoic shales to modern marine settings, where marine dissolved and sedimentary delta(6

227 This is especially true in microbial settings where differential expression and regulation of

228 on; however, this cannot be in place in most settings where detection is critical, e.g., in hospital

229 alpha-emitters are highly efficacious in MRD settings, where isolated cells and small tumor clusters

230 Furthermore, in a more natural setting where both sources of information were available

231 have already been adopted in the neoadjuvant setting where treatment toxicity will not be compounded

232 anic solvents are ubiquitous in occupational settings where they may contribute to risks for carcinog

233 chanisms for retaining iron in surface ocean settings where it limits productivity.

234 xity is illustrated by the identification of settings where autophagy acts potently to either promote

235 may be estimated without bias in a number of settings where researchers might otherwise assume that b

236 Our results considerably extend the range of settings where high-dimensional regression adjustments a

237 perturbing gene deactivation in a variety of settings where the network might operate.

238 al evaluation in a broad number of oncologic settings where mTOR signaling has a pathogenic role.

239 ormed efficiently in large surveys and other settings where approximate VA should be measured.

240 ther study of Id/KLH is recommended in other settings where efficacy may be further enhanced as in fi

241 tand neural and behavior mechanisms in other settings where emergent group-level activity exhibits mi

242 eful in high-prevalence areas or in outbreak settings where rapid carbapenemase detection is critical

243 ecule may be useful in multiple pathological settings where LRP1 blockade has been shown to be effect

244 findings suggest that in true physiological settings where multiple growth factors are present, acti

245 ocin--most are not feasible in resource-poor settings where many births occur at home.

246 idly to disease, especially in resource-poor settings where mortality is greater than 50% by 2 years

247 are particularly important in resource-poor settings where we may have underestimated cases.

248 m is particularly suitable for resource-poor settings, where centralized laboratory facilities, funds

249 In resource-poor settings, where limited drug options are the rule, when

250 Physicians and nurses from practice settings where advance care planning typically takes pla

251 Otest kits may be reused in a low prevalence setting where cost issues remain paramount.

252 olving muscle tissue and the proinflammatory setting, where inflamma-miRs and myo-miR-206 mediate the

253 ormance of standard MI and MID in regression settings where data were missing on both the outcome and

254 ver, we show that in a biologically relevant setting where synapses introduce an unavoidable amount o

255 zation at primary care clinics and in remote settings, where resources are limited.

256 Its use should be reserved for research settings where treatment regimens and imaging conditions

257 recursor converters, miEAA supports research settings where older releases of miRBase are in use.

258 t directly applicable to laboratory research settings, where adaptable, inexpensive and predictable p

259 ation in genomics studies and other research settings, where covariances differ among classes.

260 B to EDs, especially within limited resource settings where emergency medicine is a new specialty.

261 it global health through use in low-resource settings where central hematology laboratories are not a

262 In low-resource settings where disease burdens remain high and many heal

263 s global relevance, we focus on low-resource settings where rates of poverty are highest and access t

264 ts are not readily available in low-resource settings where the burden of HIV is highest.

265 made increasingly available in low-resource settings where they are most needed.

266 ion ASSURED criteria for use in low resource settings, where laboratory-based analytical procedures a

267 the efficacy of TAP blocks in low-resourced settings where patients do not have dependable access to

268 mial infection occurs in resource-restricted settings where barriers to transmission are lower.

269 dress whether this applies to urban riparian settings, where discharging groundwater may potentially

270 ility of PPV is higher in the operating room setting, where fluid strategies made on the basis of PPV

271 less well equipped laboratories and in rural settings where resources are limited.

272 ciency of biologically plausible socialtaxis settings, where agents share little or no information an

273 thdrawn have been less successful in the SOT setting where continued immunosuppression therapy is nec

274 articipant has no power, than in a strategic setting, where the other participant can punish unfair b

275 Improving care in such settings, where most health care practitioners do not ha

276 io is different from the standard supervised setting, where each classifier's accuracy can be assesse

277 WOT should be tested in high-burden TB settings, where it may substantially support low- and mi

278 We study regression M-estimates in the setting where p, the number of covariates, and n, the nu

279 In the setting where the parents donate to the F1 offspring, re

280 closure and perception of risk depend on the setting where partners are encountered.

281 que of canonical correlation analysis to the setting where original individual-level records are not

282 patients, and should be available in all the settings where they access care.

283 However, the settings where this strategy would be cost effective in

284 t on public health are best addressed in the settings where such conditions are most prevalent (ie, j

285 Information is summarized within the settings where children live, learn, and play (early car

286 In a therapeutic setting where CpG was administered after allergen sensit

287 ections is a major cause of concern in these settings where alternative effective treatment is unavai

288 nterquartile range, 2.8-16.8 months) in this setting where viral load monitoring was available.

289 In this setting, where local properties determine global propert

290 weight HA can cross-link CD44 only in those settings where it predominates over fragmentary LMW-HA,

291 atios and may be particularly well-suited to settings where an exposure propensity score is difficult

292 sibility was explored in a military training setting, where rates of febrile respiratory illness (FRI

293 plication of ctDNA in this early phase trial setting where broad genomic profiling of contemporaneous

294 ess have been described in the primary tumor setting, where the balance of protumor and antitumor res

295 ontrast with the intuitive and commonly used setting where capacity of a line is a fixed factor of it

296 to test potential therapeutics in an in vivo setting where GNAQ(Q209L) mutations contribute to both t

297 erns in these data, especially in vulnerable settings where even small numbers and low rates are impo

298 n born in Hong Kong, a developed non-Western setting, where many children have migrant parents from m

299 ce and engineering research in the very work settings where laboratory members interact.

300 andling hazardous drugs in current workplace settings where the hierarchy of controls is consistently